Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) Director Sells 14,167 Shares of Company Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Laura Brege sold 14,167 shares of the firm’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $94.21, for a total transaction of $1,334,673.07. Following the transaction, the director directly owned 15,703 shares of the company’s stock, valued at approximately $1,479,379.63. This represents a 47.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mirum Pharmaceuticals Stock Up 0.7%

Shares of MIRM traded up $0.63 during midday trading on Friday, hitting $93.96. The company had a trading volume of 321,083 shares, compared to its average volume of 831,114. The stock has a market cap of $6.13 billion, a price-to-earnings ratio of -6.07 and a beta of 0.75. The company’s 50 day moving average price is $88.92 and its 200 day moving average price is $98.44. The company has a quick ratio of 1.98, a current ratio of 2.07 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 52 week low of $63.23 and a 52 week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.38). The company had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. The business’s revenue for the quarter was up 39.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.05 EPS. On average, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.47 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Citigroup upped their price objective on Mirum Pharmaceuticals from $184.00 to $194.00 and gave the company a “buy” rating in a research note on Wednesday. Citizens Jmp lifted their target price on Mirum Pharmaceuticals from $144.00 to $167.00 and gave the stock a “market outperform” rating in a research report on Wednesday, November 4th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $155.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 4th. Raymond James Financial reiterated a “strong-buy” rating and issued a $189.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 4th. Finally, Wall Street Zen lowered Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $155.56.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MIRM. Janus Henderson Group PLC raised its stake in Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after acquiring an additional 880,505 shares during the period. Jupiter Topco LLC bought a new position in shares of Mirum Pharmaceuticals during the second quarter valued at approximately $691,672,000. BlackRock Inc. bought a new position in shares of Mirum Pharmaceuticals during the second quarter valued at approximately $513,945,000. William Blair Investment Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $164,453,000. Finally, Rock Springs Capital Management LP raised its position in shares of Mirum Pharmaceuticals by 6.4% during the 1st quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company’s stock worth $74,947,000 after purchasing an additional 49,000 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.